Efficacy of Pharmacological and Bioactive Compounds on Serum Ovalbumin-Specific Immunoglobulin E and Nasal Symptom Scores in Ovalbumin-Induced Allergic Rhinitis Animal Models: A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.59141/jrssem.v5i11.1524Keywords:
allergic rhinitis, ovalbumin, immunoglobulin e, natural compounds, phytochemicalsAbstract
Allergic rhinitis (AR) is a highly prevalent immunoglobulin E (IgE)-mediated inflammatory disease of the nasal mucosa. Ovalbumin (OVA)-induced AR animal models are widely used to evaluate potential therapeutic agents; however, no quantitative synthesis of treatment effects across pharmacological interventions has been performed. This study aimed to systematically review and meta-analyse the effects pharmacological and bioactive interventions on serum OVA-specific IgE levels, nasal rubbing scores, and nasal sneezing scores in OVA-induced AR animal models. PubMed, EMBASE, Scopus were searched from inception through 22 May 2026. Eligible studies were in vivo experimental studies using OVA-sensitised and intranasally challenged rodent models with at least one pharmacological intervention and an untreated or vehicle control group. Risk of bias was assessed using the SYRCLE tool. Standardised mean differences (SMDs) were pooled using random-effects models with the restricted maximum likelihood (REML) estimator and the Hartung–Knapp–Sidik–Jonkman (HKSJ) adjustment. Analyses were conducted in R using the metafor package. Fourteen intervention studies met the inclusion criteria. Pharmacological and bioactive interventions significantly reduced serum OVA-specific IgE levels (pooled SMD = ?3.03; 95% CI: ?4.77 to ?1.28; I² = 78.1%), nasal rubbing scores (pooled SMD = ?5.24; 95% CI: ?7.17 to ?3.31; I² = 80.2%), and nasal sneezing scores (pooled SMD = ?4.29; 95% CI: ?5.79 to ?2.78; I² = 78.5%). Substantial heterogeneity was observed across all outcomes. Leave-one-out sensitivity analyses confirmed the robustness and directionality of the pooled estimates. Pharmacological and bioactive interventions consistently and significantly attenuated serum OVA-specific IgE levels and nasal symptom scores in OVA-induced AR animal models.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ayunita Tri Wirattami, Iriana Maharani, Edi Handoko, Nanik Setijowati, Shanti Andri Sakarisa
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International. that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
